Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Is now the time to look at the biotech flyer? The post Telix shares slip 11% from highs. Time to buy this high flying biotech ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...